Drug Type Autologous CAR-T |
Synonyms Anti-CD7 CAR-T- cell therapy (PersonGen Biomedicine), Autologous CD7CART cells PersonGen Biotherapeutics, PA3 17 + [1] |
Target |
Mechanism CD7 inhibitors(T-cell antigen CD7 inhibitors), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CD7 Positive Neoplasms | Phase 1 | CN | 21 Feb 2022 | |
Extranodal NK-T-Cell Lymphoma | Phase 1 | CN | 25 Aug 2019 | |
Recurrent T Lymphoblastic Lymphoma | Phase 1 | CN | 25 Aug 2019 | |
T-cell Acute Lymphoblastic Leukemia/Lymphoma | IND Application | CN | 21 Feb 2022 |
Phase 1 | 11 | cgqvmfeooo(shiyllksre) = 患者均出现了CRS(1-2级, n=10;4级, n=1) xaefksqggm (eapmglineo ) View more | - | 21 Sep 2022 | |||
Phase 1 | T-cell Acute Lymphoblastic Leukemia/Lymphoma CD7 Positive | 8 | wcpiasnqdf(emcapixzqz) = fgnioivpxd nzphrbdtog (vdpsjwbrma ) View more | Positive | 01 Jul 2022 |